- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00264706
PolyArginine Treated vEiN grafTs (PATENT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
LT-1951 is an aqueous solution of NONA-L-ARGININE. The drug efficiently penetrates into vascular tissues like the saphenous vein and supplies the tissue with a sustained reservoir of L-arginine, the substrate for production of nitric oxide. Nitric oxide (NO) is an important vasoactive and cell signaling compound implicated in suppression of neointimal hyperplasia. NO limits neointimal hyperplasia by inhibiting monocyte chemotaxis and adherence, platelet adherence and aggregation, and vascular smooth muscle cell proliferation.
A dramatic reduction of neointimal hyperplasia following treatment with LT-1951 has been demonstrated in preclinical vein to artery interposition studies in several animal models. Marked improvement following a single ex vivo application of LT-1951 in interposition grafts demonstrated that the beneficial effect of the drug is not dependent upon continued treatment of the grafted tissue.
In the PATENT trial, saphenous vein grafts are harvested in the usual manner from the patient's leg and are bathed in LT-1951 or placebo ex vivo (at normal pressure and temperature) before being rinsed and implanted into the patient. Because LT-1951 is applied only to the graft, there is minimal systemic exposure and risk to the patient.
All patients in this study will receive treatment with both NONA-L-ARGININE and vehicle control. This within-patient, placebo-controlled, study will be double-blinded and randomized. For each patient, one of the comparable vein grafts will receive treatment with placebo, while the other will receive treatment with NONA-L-ARGININE. Any third vein graft used in the procedure will be treated as per the first vein graft, while any fourth vein graft will be treated as per the second vein graft.
The first cohort of 20 patients will be the primary safety subgroup. This subgroup will be evaluated in combination with a second cohort of 30-80 patients for assessment of efficacy endpoints. During follow-up, all patients will have clinical visits at 6 weeks, which will include Computed Tomographic Angiography (CTA). Patients will undergo Intravascular Ultrasound-coronary angiography (IVUS-angio) at 12 months and optional CTA at 6, 12 and 24 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Toronto General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject must be 35-85 years of age and able to give informed consent.
- Coronary artery disease requiring bypass grafting using at least two saphenous vein bypass grafts carried out through median sternotomy and utilizing cardiopulmonary bypass.
- Use of an approved statin anticipated for at least 24 months after surgery.
- Subject must not be a candidate for concurrent ventricular surgical restoration, AICD placement, or valvular surgery.
- Agreeable to CTA at 6 weeks and IVUS intervention at 12-months post-CABG. Subjects agreeable to additional CTA at 6, 12 and 24 months preferred.
Exclusion Criteria:
- Acute traumatic injury or vasculitis.
- Insulin-dependent diabetes.
- Procedure is for revision for an existing bypass graft.
- Procedure is to be minimally invasive (except for harvesting of the graft segment).
- Concurrent cardiac valvular surgery.
- Patients with any medical condition that, in the investigator's judgment, makes the patient ineligible or places the patient at undue risk (e.g. conditions that preclude standard invasive follow-up procedures such as IVUS and angiography, i.e. renal failure, bleeding diathesis, or peripheral vascular disease preventing catheterization via the groin).
- Subject has clinical evidence of infection that the Investigator deems significant to the completion of the procedure, or that could compromise the subject's safety.
- Subject has recent history (within past 6 months) of alcohol or drug abuse.
- If female, subject is pregnant or trying to become pregnant.
- Calculated creatinine clearance < 30 mls/min for non-diabetics or < 50 mls/min for non-insulin dependent diabetics.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Participant
Internal control study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety - as assessed by the nature and frequency of clinical adverse event at 6 weeks post-surgery.
Time Frame: 6 weeks
|
6 weeks
|
Efficacy - Volume obstruction of the vein grafts measured by IVUS at 1 year.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
1. Volume obstruction adjacent to the proximal and distal anastomoses, and within the body of the graft; 2. Intima:media ratio; 3. Minimal and maximal luminal diameter; and, 4. lumen volume:vessel volume.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephanie Brister, M.D., Toronto General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Lumen-01-CS-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Saphenous Vein Graft Disease
-
Catholic University of the Sacred HeartCompletedSaphenous Vein Graft Disease
-
Boston Scientific CorporationCompletedSymptomatic Ischemic Saphenous Vein Graft DiseaseUnited States, Canada
-
Boca Raton Regional HospitalPfizerCompletedSaphenous Vein Graft DiseaseCanada, United States
-
North Texas Veterans Healthcare SystemNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedAortocoronary Saphenous Vein Bypass Graft Atherosclerosis | Intermediate Saphenous Vein Graft LesionsUnited States
-
Tianjin Chest HospitalUnknownPercutaneous Coronary Intervention | Saphenous Vein Graft Disease | Major Adverse Cardiovascular Events | Virtual Histology Intravascular UltrasoundChina
-
Institute of Cardiology, Warsaw, PolandUnknownStenosis in Saphenous Vein Graft, Drug Eluting StentPoland
-
Boca Raton Regional HospitalAstraZeneca; Ottawa Heart Institute Research CorporationCompletedSaphenous Vein Graft DiseaseUnited States, Canada
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
-
Charles University, Czech RepublicActive, not recruiting
-
Satoshi HanadaCompleted
Clinical Trials on Nona-L-arginine
-
Emory UniversityNational Center for Complementary and Integrative Health (NCCIH); Children's...CompletedSickle Cell Disease | Vaso-occlusive Pain EpisodeUnited States
-
Instituto de Oncología Ángel H. RoffoCompletedUnresectable Multiple Brain Metastases
-
Juliano CasonattoUnknown
-
University Hospital, Strasbourg, FranceCompletedSkeletal Muscle Ischemia | Severe Lower Limb Ischemia | Mitochondrial DysfunctionFrance
-
UCSF Benioff Children's Hospital OaklandCompletedVaso-occlusive Pain EpisodesUnited States
-
Hospital Civil de GuadalajaraNot yet recruitingArginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth CurveFetal Growth Retardation
-
Alexandra Hospital, Athens, GreeceUniversity of AthensUnknown
-
Maastricht University Medical CenterNovartis Medical NutritionCompletedSepsis | Septic Shock
-
Centro Universitario de TonaláWithdrawn
-
Emory UniversityRecruiting